⌘K

17:15:52·1647d

INSIDERFilingvia Quantisnow

SEC Form 3 filed by new insider White Michael Anthony

ByQuantisnow·Wall Street's wire, on your screen.

IDYA· IDEAYA Biosciences Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

IDYA
IDEAYA Biosciences Inc.
Health Care

Recent analyst ratings

Jan 7UpdateUBS$50.00
Nov 24UpdateTruist-
Sep 18UpdateGuggenheim$50.00
Sep 4UpdateBarclays$40.00
Sep 4UpdateCitizens JMP$41.00
Jul 22UpdateTD Cowen-

Related

PR22h
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SEC1d
SEC Form DEFA14A filed by IDEAYA Biosciences Inc.
PR1d
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
SEC2d
SEC Form DEF 14A filed by IDEAYA Biosciences Inc.
PR10d
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
SEC18d
SEC Form 8-K filed by IDEAYA Biosciences Inc.
PR18d
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
PR21d
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026